Journal article
PEGylated IL-10: Clinical Development in Cancer Immunotherapy, Where to Go?
Current Oncology Reports, Vol.25, pp.115-122
2023
PMID: 36585961
Abstract
Purposeof Review:
The purpose of this review is to discuss the current understanding of the pegilodecakin (PEGylated interleukin 10) and its role in the inhibition of tumour growth and metastasis. This review also focuses on clinical data published to date that have evaluated the efficacy and safety of pegilodecakin.
Recent Findings:
Pegilodecakin has shown significant promise in preclinical models, notable for decreased tumour burden and fewer sites of metastatic disease across various malignancies. It has been most widely assessed in a phase I/Ib clinical trial against several solid tumours, leading to the phase II and III clinical trials containing pegilodecakin and its combination with other current treatments. However, the updated data have not shown higher efficacy in renal cell carcinoma, metastatic non-small cell lung cancer or pancreatic cancer, with respect to the controls, yet the adverse events presented more mixed results. Further investigation into combination therapies including pegilodecakin is ongoing.
Summary:
Pegilodecakin showed promise in preclinical and phase I clinical trials on its efficacy in several solid tumours, with expected regulation of IL-10 signalling pathway observed. However, the phase II and III trials did not justify its application as potential immunotherapy in selected cancers. Further evaluation of pegilodecakin’s efficacy in other cancers, either as monotherapy or in combination with the current treatments, is worth investigating clinically, which warrants to better understand its potential clinical utility.
Details
- Title
- PEGylated IL-10: Clinical Development in Cancer Immunotherapy, Where to Go?
- Authors
- Bernardo Cavallazzi Sebold (Author) - University of the Sunshine Coast, Queensland, Centre for BioinnovationGuoying Ni (Author) - University of the Sunshine Coast, Queensland, Centre for BioinnovationJunjie Li (Author) - Guangdong Pharmaceutical UniversityHejie Li (Author) - University of the Sunshine Coast, Queensland, School of Science, Technology and EngineeringXiaosong Liu (Corresponding Author) - First Affiliated Hospital of Guangdong Pharmaceutical UniversityTianfang Wang (Corresponding Author) - University of the Sunshine Coast, Queensland, Centre for Bioinnovation
- Publication details
- Current Oncology Reports, Vol.25, pp.115-122
- Publisher
- Springer Healthcare
- Date published
- 2023
- DOI
- 10.1007/s11912-022-01355-4
- ISSN
- 1534-6269
- PMID
- 36585961
- Grant note
- 2020A1515010855 / Natural Science Foundation of Guangdong Province 2019A008 / Deng Feng project of Foshan First People's Hospital 2016A020213001 / Guangdong Science and Technology Department 31971355 / National Natural Science Foundation of China
- Organisation Unit
- School of Science and Engineering - Legacy; GeneCology Research Centre - Legacy; School of Science, Technology and Engineering; Centre for Bioinnovation
- Language
- English
- Record Identifier
- 99696997302621
- Output Type
- Journal article
Metrics
36 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- International collaboration
- Web Of Science research areas
- Oncology
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: SDGs from InCites